- Market Realist•yesterday
Among the 24 analysts surveyed by Bloomberg for AbbVie (ABBV), 54.5% gave it “buy” ratings, and 40.9% gave it “hold” ratings.
- The Wall Street Journal•2 days ago
Pfizer’s $14 billion deal to buy Medivation and its prostate-cancer drug Xtandi is the latest in a long line of big pharmaceutical company acquisitions of smaller companies with prized assets. Here is ...
- ETF Trends•2 days ago
Pfizer (NYSE: PFE) announced a $14 billion deal to acquire cancer drug developer Medivation (NasdaqGS: MDVN), propelling the broader biotechnology exchange traded funds higher on speculation of more deals ...
Celgene Corporation (CELG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||113.22 x 300|
|Ask||113.27 x 200|
|Day's Range||112.30 - 115.49|
|52wk Range||93.05 - 128.39|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||47.65|
|Avg Vol (3m)||4,484,840|
|Dividend & Yield||N/A (N/A)|